FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
1. Name and Address of Reporting Person* Barnett Eva Renee				2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 10/04/2021							X Officer (give title below) Other (specify below) Chief Financial Officer				
(Street) NEW YORK, NY 10018				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui							red, Dispo	osed of, or I	Beneficially	Owned	
(Instr. 3) Date			2. Transaction Date (Month/Day/Year	Executi any		Code (Instr. 8)	(A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficial Reported	nt of Securities ally Owned Following Transaction(s)		Form:	7. Nature of Indirect Beneficial	
				(Month	n/Day/Year	Code	V	Amour	(A) or (D)	Price	(Instr. 3 ar	3 and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock (1) 10/04/2021					A		59,500 (2)	0 A	\$ 0	59,500			D		
						ies Acquire	ed, Di	sposed o	of, or Ben	eficial		OMB conf	rol numbe	r.	
	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Da	te, if Transaction I Code (Instr. 8)		5. 6. Date and Ex		convert ate Exerc Expiration	convertible securi te Exercisable xpiration Date		itle and ount of erlying urities r. 3 and		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownersh Form of Derivatir Security Direct (I or Indire	vee Ownership (Instr. 4)
					Code V	4, and 5) (A) (D)	Date Exerc		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners		,											
					Relationships										
Reporting Owner Name / Address Director				10%	10% Officer				Other						

Chief Financial Officer

Signatures

Barnett Eva Renee

C/O IMMUNOVANT, INC.

NEW YORK, NY 10018

320 W 37TH STREET, 6TH FLOOR

/s/ Eva Renee Barnett	10/05/2021
**Signature of Reporting Person	Date

Owner

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the number of shares underlying restricted stock units awards ("RSUs").
- (2) The RSUs vest in their entirety on January 1, 2022, subject to the Reporting Person providing continuous service to the Issuer as of such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.